-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
-
Summary
-
Ambrx Biopharma Cayman, Inc. quarterly and annual Revenues in USD history and change rate from 31 Dec 2019 to 30 Jun 2023.
- Ambrx Biopharma Cayman, Inc. Revenues for the quarter ending 30 Jun 2023 was $1,123,000, a 14% decline year-over-year.
- Ambrx Biopharma Cayman, Inc. annual Revenues for 2022 was $7,402,000, a 0.71% decline from 2021.
- Ambrx Biopharma Cayman, Inc. annual Revenues for 2021 was $7,455,000, a 45% decline from 2020.
- Ambrx Biopharma Cayman, Inc. annual Revenues for 2020 was $13,671,000, a 33% increase from 2019.